Per Richo24's link above:Rhodes: Most certainly you could expect to continue to see that.
As long as the program targets a mechanism and that causal biology that we think is important, for the initiation and progression of disease, we would be interested in hearing about it and having a conversation about it.
Together with our existing series of partnerships, we’re certainly interested in evaluating other high quality opportunities that are consistent with our strategy. And that strategy really focuses on disease-modifying therapies in neurodegenerative diseases like Alzheimer’s disease and ALS, in neuromuscular diseases and then neuroinflammatory diseases.
Per Richo24's link above:Rhodes: Most certainly you could expect...
-
- There are more pages in this discussion • 4,632 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |